VTRSViatris

Each row is one issuer’s token for Viatris, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of Viatris, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
VTRSx	xStocks	ETHSOLHYPETONARBINKMNTBNBXLYROP	—

Deployments come from the instrument registry, generated 2026-09-30. A chain listed here is one the issuer has deployed on, not a promise that a market exists on it.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Type

Common stock

Sector

Healthcare › Pharmaceuticals

Exchange

Nasdaq

Listed since

Feb 23, 1973

Shares outstanding

1.15B

Employees

30,000

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.